Starting January 1, 2026 C.E., California will sell state-branded insulin pens directly to residents for a maximum of $55 for a five-pack — just $11 per pen. The announcement marks the first time a U.S. state has manufactured and sold its own low-cost insulin, using a publicly backed program to undercut pharmaceutical prices that can run four to seven times higher for the same medication.
At a glance
- CalRx insulin: California’s state-backed program will sell biosimilar long-acting insulin glargine pens at a maximum retail price of $55 for a five-pack, compared to brand-name equivalents that can cost pharmacies up to $411 per pack.
- Civica Rx contract: The state signed a $50 million contract with nonprofit manufacturer Civica Rx, which subcontracted with Biocon Biologics to produce the insulin — sold to pharmacies at $45 per five-pack before the $55 retail cap.
- Co-pay cap: A separate new California law limits consumer insulin co-payments to $35 per month, adding a second layer of protection for insured residents alongside the state-manufactured supply.
Why insulin prices got this high
Insulin has been around for over a century. The scientists who first isolated it in 1921 C.E. sold the patent for one dollar each, intending the drug to stay accessible forever. That plan did not survive contact with the American pharmaceutical market.
A handful of large companies came to dominate global insulin production, and U.S. prices climbed to among the highest in the world. A 2022 C.E. survey by Charity Rx found that nearly 80% of American insulin users said the drug’s price had created financial hardship for themselves or someone they care for. People have rationed doses, skipped injections, and died from complications that a $11 pen could have prevented.
Diabetes affects more than 38 million Americans — over 11% of the population — and falls hardest on Black, Hispanic, and Native American communities, who face higher rates of the disease and steeper barriers to consistent care. Cost is among the most actionable of those barriers.
How the CalRx model works
California’s CalRx program, launched in 2020 C.E., contracts with manufacturers to produce generic and biosimilar pharmaceuticals, then sells them at near-cost prices. For insulin, the state partnered with Civica Rx — a nonprofit formed by a coalition of health systems specifically to combat drug shortages and high prices.
Civica Rx’s Virginia manufacturing plant will eventually produce three common insulin types: glargine, aspart, and lispro. The California rollout begins with a long-acting biosimilar glargine pen produced by Biocon Biologics. Separately, Civica Rx is also offering the five-pack nationwide starting in January through a partnership with Blue Cross Blue Shield.
The CalRx program previously made naloxone nasal spray available at a discounted $24 for a twin pack to consumers, and free to eligible organizations. Insulin is its most significant product yet by scale of potential impact.
“California didn’t wait for the pharmaceutical industry to do the right thing — we took matters into our own hands,” Governor Gavin Newsom said in a statement. “No Californian should ever have to ration insulin or go into debt to stay alive.”
What experts are saying
The American Diabetes Association called the program “an important, incremental step to offer more options for affordable insulin.” Christine Fallabel, the ADA’s director of State Government Affairs and a person living with type 1 diabetes, told Healthline that the organization applauds any effort to improve affordability for people who depend on insulin to survive.
Kanwar Kelley, MD, co-founder of Side Health in Orinda, California, called the program promising — and noted that capping individual out-of-pocket costs could push other manufacturers to lower their own prices, reducing the need for coupons and savings programs that often require patients to navigate complex paperwork just to afford a basic medication.
Kelley also raised legitimate concerns worth watching. If demand for the lower-priced CalRx insulin is high — which seems likely — Civica Rx will need to scale production quickly to avoid shortfalls. Some patients may also be reluctant to switch from insulin brands they’ve used for years, even if the biosimilar is clinically equivalent. And if other manufacturers reduce their production in response to lost market share, the overall insulin supply could face pressure.
A model other states are watching
Several states have already passed laws capping out-of-pocket insulin costs, and the federal government set a $35 monthly Medicare co-pay cap under the Inflation Reduction Act. But patient cost caps don’t fix what the broader system pays — and those upstream costs drive insurance premiums, Medicaid budgets, and employer health plans alike.
State-backed manufacturing is a more direct intervention. If CalRx proves that a state government can produce and distribute a complex pharmaceutical product reliably and affordably, it opens the door for similar programs targeting other high-cost drugs — EpiPens, certain cancer treatments, and other medications where patent protections and market consolidation have pushed prices far beyond manufacturing costs.
“California is a big market state that has considerable tax revenue to be able to implement this plan; other states may not be able to do so on the same scale,” Kelley noted. But he added that the federal government’s interest in lowering prescription drug prices could help other states adopt similar models over time. For the 3.2 million Californians living with diabetes, the question of whether the model scales nationally matters — but it’s secondary to whether the $11 pen arrives on time at their pharmacy in January.
You can learn more about how states and communities are building equitable access to essential resources through the Good News for Humankind archive on global health.
Read more
For more on this story, see: Healthline
For more from Good News for Humankind, see:
- Renewables now make up at least 49% of global power capacity
- Marie-Louise Eta becomes the first female head coach in men’s top-flight European football
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
China plans to double its already massive clean energy supply by 2035
China’s new climate pledge to the United Nations sets a target of 3,600 gigawatts of wind and solar power by 2035 — more than the entire electricity-generating capacity of the United States today, and roughly double what China has already built. The commitment is woven into the country’s next Five-Year Plan, which directs state banks, provinces, and manufacturers to move in the same direction. Because China makes about 80% of the world’s solar panels, every factory it scales up makes clean energy cheaper for buyers in Africa, Southeast Asia, Latin America, and everywhere else. That ripple effect is what makes…
-
Doctors hail first breakthrough in asthma and COPD treatment in 50 years
Benralizumab, a single injection given during an asthma or COPD attack, outperformed the steroid pills that have been the only emergency option since the 1970s. In a King’s College London trial of 158 patients, those who got the shot had four times fewer treatment failures over 90 days, along with easier breathing and fewer follow-up visits. Because steroids carry real risks with repeated use — diabetes, osteoporosis, and more — a genuine alternative could change daily life for millions of people who live in fear of the next flare-up. After a half-century of stalled progress on diseases that claim 3.8…
-
Mexico launches universal healthcare for all 133 million citizens
Mexico universal healthcare is now officially a reality, with the country launching a system designed to cover all 133 million citizens through the restructured IMSS-Bienestar network. Before this reform, an estimated 50 million Mexicans had no formal health insurance, with rural and Indigenous communities bearing the heaviest burden of untreated illness and medical debt. The new system severs the long-standing tie between employment and healthcare access, providing free consultations, medicines, and hospital services regardless of income. If implemented effectively, Mexico’s move could serve as a powerful model for other middle-income nations still navigating fragmented, inequitable health systems.
